human dendritic cells

Jagged-1 (188-204)is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-αB activation.

PSMα3 TFA is a peptide used to direct dendritic cells (DCs) towards a tolerogenic state, critical for DC vaccination approaches. It modulates human monocyte-derived DCs by disrupting maturation induced by TLR2 or TLR4, suppressing pro-inflammatory and anti-inflammatory cytokine secretion, and reducing antigen assimilation. Notably, PSMα3 TFA is a significant toxin secreted by highly virulent methicillin-resistant Staphylococcus aureus (MRSA) strains [1] [2].

HOXB7 (8-25), a peptide fragment derived from homeobox B7 (HOXB7)—a key controller of cell growth and oncogene activator—facilitates antigen presentation when pulsed onto dendritic cells obtained from human peripheral blood mononuclear cells (PBMCs). This process promotes the activation and interferon-gamma (IFN-γ) production by CD4+ helper T cells, triggering targeted and broad-spectrum antitumor responses.

Surfactant protein A (SP-A) (196-215) is a synthetic peptide derived from the C-terminal carbohydrate recognition domain of human SP-A, specifically amino acids 196-215. This peptide suppresses LPS-induced TNF-α release in JAWSII mouse dendritic cells at 1 and 10 µM concentrations and promotes phagocytosis of P. aeruginosa at a 75 µM concentration. Furthermore, intratracheal administration of SP-A (196-215) at a dose of 50 µg per animal reduces disease severity and lung colony-forming units in mice infected with P. aeruginosa.

EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model.